{"id":"W4401876575","doi":"10.1016/s2152-2650(24)00986-8","title":"Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003135617,0.001302327,0.002982879,0.0003948789,0.0004717082,0.001145862,0.001140921,0.001347499,0.004327668],"category_scores_gemma":[0.002587499,0.0005024935,0.004312849,0.0004942168,0.0008842402,0.001163817,0.0007480697,0.003801662,0.0005808466],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001259342,"about_ca_system_score_gemma":0.001079953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001012991,"about_ca_topic_score_gemma":0.002613547,"domain_scores_codex":[0.9985409,0.0009075967,0.0000974279,0.0001746144,0.0001275637,0.0001519388],"domain_scores_gemma":[0.9980903,0.0006523409,0.0005613103,0.0001289787,0.00009633892,0.0004706573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.968133,0.002645508,0.004593421,0.0005450948,0.005471404,0.00004164685,0.00004605242,0.0008321828,0.001202289,0.0001251929,0.001566487,0.0147977],"study_design_scores_gemma":[0.9066589,0.06573436,0.01908648,0.00009239981,0.005024088,0.0001197943,0.00007186311,0.0008152504,0.0005136947,0.0004156217,0.001424282,0.0000432056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842037,0.00837136,0.0003921346,0.0008692215,0.0002969198,0.0008136136,0.003157143,0.0000550868,0.001840799],"genre_scores_gemma":[0.9880639,0.002297116,0.00100193,0.001283601,0.0003148035,0.001205539,0.00450965,0.00002297504,0.001300426],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004327668,"threshold_uncertainty_score":0.01658297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03394083343133087,"score_gpt":0.3328008750787567,"score_spread":0.2988600416474259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}